X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs GLENMARK PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH GLENMARK PHARMA PANACEA BIOTECH/
GLENMARK PHARMA
 
P/E (TTM) x 22.7 17.8 127.2% View Chart
P/BV x 3.1 3.2 94.5% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 PANACEA BIOTECH   GLENMARK PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
GLENMARK PHARMA
Mar-17
PANACEA BIOTECH/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs149993 15.0%   
Low Rs82729 11.3%   
Sales per share (Unadj.) Rs84.1325.5 25.8%  
Earnings per share (Unadj.) Rs-18.339.3 -46.6%  
Cash flow per share (Unadj.) Rs-6.748.7 -13.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs83.7159.2 52.6%  
Shares outstanding (eoy) m61.25282.17 21.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.42.6 51.9%   
Avg P/E ratio x-6.321.9 -28.8%  
P/CF ratio (eoy) x-17.217.7 -97.4%  
Price / Book Value ratio x1.45.4 25.5%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m7,074242,991 2.9%   
No. of employees `0002.813.0 21.2%   
Total wages/salary Rs m1,44916,408 8.8%   
Avg. sales/employee Rs Th1,874.17,083.9 26.5%   
Avg. wages/employee Rs Th527.01,265.4 41.6%   
Avg. net profit/employee Rs Th-407.7855.1 -47.7%   
INCOME DATA
Net Sales Rs m5,15491,857 5.6%  
Other income Rs m100374 26.7%   
Total revenues Rs m5,25492,230 5.7%   
Gross profit Rs m-76620,367 -3.8%  
Depreciation Rs m7112,644 26.9%   
Interest Rs m1,5032,373 63.3%   
Profit before tax Rs m-2,88115,724 -18.3%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771-810 -218.8%   
Tax Rs m173,827 0.4%   
Profit after tax Rs m-1,12111,088 -10.1%  
Gross profit margin %-14.922.2 -67.1%  
Effective tax rate %-0.624.3 -2.4%   
Net profit margin %-21.812.1 -180.3%  
BALANCE SHEET DATA
Current assets Rs m3,81068,746 5.5%   
Current liabilities Rs m8,36527,027 31.0%   
Net working cap to sales %-88.445.4 -194.6%  
Current ratio x0.52.5 17.9%  
Inventory Days Days15685 183.2%  
Debtors Days Days6796 70.4%  
Net fixed assets Rs m14,48024,132 60.0%   
Share capital Rs m61282 21.7%   
"Free" reserves Rs m90344,643 2.0%   
Net worth Rs m5,12744,925 11.4%   
Long term debt Rs m5,83245,363 12.9%   
Total assets Rs m19,433117,639 16.5%  
Interest coverage x-0.97.6 -12.0%   
Debt to equity ratio x1.11.0 112.6%  
Sales to assets ratio x0.30.8 34.0%   
Return on assets %2.011.4 17.2%  
Return on equity %-21.924.7 -88.6%  
Return on capital %3.619.1 19.0%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,53956,152 2.7%   
Fx outflow Rs m9428,084 11.7%   
Net fx Rs m59748,068 1.2%   
CASH FLOW
From Operations Rs m5996,574 9.1%  
From Investments Rs m-438-7,124 6.1%  
From Financial Activity Rs m-3035,432 -5.6%  
Net Cashflow Rs m-1411,992 -7.1%  

Share Holding

Indian Promoters % 74.5 48.3 154.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 6.9 8.7%  
FIIs % 1.3 34.4 3.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.5 224.8%  
Shareholders   10,259 56,727 18.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  SUVEN LIFE  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Up; ONGC & Tata Steel Top Gainers(Closing)

Indian share markets ended the day on a strong note. At the closing bell, the BSE Sensex finished higher by 262 points. While, the NSE Nifty finished up by 91 points.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


May 25, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS